CTNNB1 and hepatocellular carcinoma: For example, a recently developed metabolic network classified HCC patients into three subgroups (iHCC1–iHCC3), where the iHCC2 phenotype was associated with aberrant Wnt signaling: 75% of iHCC2 tumors found to carry CTNNB1 mutations and displayed upregulated expression of β-catenin target genes [24].